Pan-tumor validation of FoundationOne®CDx as a companion diagnostic for RET fusions as a predictor of response to selpercatinib

BackgroundRET fusions represent a subgroup of alterations in cancer biology that exhibit sensitivity to selective RET kinase inhibitors. We analytically validated a next-generation sequencing-based companion diagnostic (CDx) to detect RET fusions in solid tumors via a comprehensive genomic profiling...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Allison van den Hout, Richard S. P. Huang, Caleb Ho, David L. Smith, Douglas A. Mata, Baljinder Kaur, Sameera R. Wijayawardana, Jennifer Wright, Anna M. Szpurka, Douglas I. Lin
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2026-05-01
Saila:	Frontiers in Oncology
Gaiak:	companion diagnostic (CDx) comprehensive genomic profiling (CGP) FoundationOne®CDx RET fusion validation
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1820286/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!